CCA
RARE icon

Column Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Column Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$60.7K Hold
1,704
– – 0.01% 294
2023
Q2 		$78.6K Buy
+1,704
New +$79K 0.01% 260

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Capital Advisors's RARE Position: Q3 2023 in Review

Column Capital Advisors held its Ultragenyx Pharmaceutical (RARE) position steady in Q3 2023 at 1,704 shares worth $60.7K. The position accounts for 0.01% of the portfolio, ranked #294.

Column Capital Advisors first reported a position in RARE in Q2 2023 and has held it in 2 quarters since. The position peaked at $78.6K in Q2 2023. 220 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

  • Column Capital Advisors held 1,704 shares of Ultragenyx Pharmaceutical worth $60.7K as of Q3 2023.
  • Column Capital Advisors left its Ultragenyx Pharmaceutical share count unchanged in Q3 2023.
  • Ultragenyx Pharmaceutical made up 0.01% of Column Capital Advisors's portfolio in Q3 2023, its #294 holding.
  • Column Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 2 quarters since.
  • Column Capital Advisors's Ultragenyx Pharmaceutical position peaked at $78.6K in Q2 2023.
  • 220 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.